羟苯磺酸钙和缬沙坦联合治疗早期糖尿病肾病的临床观察

目的:探讨羟苯磺酸钙和缬沙坦联合治疗对早期糖尿病肾病的肾脏保护作用.方法:将64例合并早期糖尿病肾病的2型糖尿病患者随机分为3组,分别给予羟苯磺酸钙(A组)、缬沙坦(B组)、羟苯磺酸钙联合缬沙坦(C组)治疗12周,观察治疗前后平均动脉压(MAP)、空腹血糖(FPG)、糖化血红蛋白(HbA1c)、尿白蛋白排出率(UAER)、血液流变学等各指标的变化情况.结果: 3组UAER均有不同程度的下降,C组下降更为显著(P<0.05);A组、C组红细胞聚集指数、全血高切粘度、全血低切粘度、血浆比粘度、纤维蛋白原及血沉较治疗前有显著下降(P<0.05).结论:羟苯磺酸钙和缬沙坦联合治疗具有良好的肾脏保护作用,是早期糖尿病肾病的有效治疗方案.

Combined Treatment of Calcium Dobesilate and Valsartan for Diabetic Nephropathy in Early Stage

Objective:To observe the clinical curative effect of combined treatment of Calcium Dobesilate and Valsartan in patients with early diabetic nephropathy.Methods:64 T2DM patients with early DN were divided into three groups:Group A was treated with Calcium Dobesilate,Group B was treated with Valsartan and Group C was combined treated with Calcium Dobesilate and Valsartan for 12 weeks,respectively.MAP,FPG,HbA1c,UAER and homorheology were compared before and after the treatment.Results:The level of UAER decreased in all the groups,especially in Group C(p<0.05);Erythrocyte aggregation index,whole blood high-shear viscosity,whole blood low-shear viscosity,plasma viscosity,fibrinogen content and ESR significantly decreased in Group A and C(p<0.05).Conclusion:Combined treatment of Calcium Dobesilate and Valsartan might protect renal function in patients with early DN.